We are developing innovative prognostic tools that permit the identification of individuals with increased risk to multiple infections (hypersusceptibility) prior to infections occurrence. A test able to predict the risk of developing multiple infections would offer profylaxis to those at risk, allowing clinicians to consider immediate prophylactic interventions other than antibiotics, while to those at low risk spare any potential side effects, such as killing the beneficial microbiota as a result of broad spectrum antibiotics usage. Widespread antibiotic use contributes to the emergence of MDR pathogens.  

Our key innovation lies on the novel patient prognostic stratification approach and tools that use the expression profiles of multiple genes, or proteins to aid in successfully delivering appropriate personalized preventative and therapeutic treatment to patients who are at high risk for infection.   As such, this methodology is going to permit individualized treatments,  and limit the use of antibiotics, promote antibiotic stewardship, streamline appropriate hospital care, reduce health care costs, and thereby improve treatment outcomes. One of our ultimate goals is host-targeted immunopotentiation and therapy that will promote the patient’s natural local and systemic defensive responses to restore robust host responses for clearing or preventing infections.  Our approach is fundamentally different from the existing standard of care that focuses on early diagnosis and treatment after infections’ occurrence.